2ο Συνέδριο Ογκολογίας της Διασποράς

Chairs: T. Makatsoris (GR), M. Liontos (GR)
09.00-09.25 DNA damage Z. Lygerou (GR)
09.25-09.50 Epigenetics in solid tumors A. Klinakis (GR)

Chairs: V. Kouloulias (GR), Α. Dimopoulos (GR)
09.50-10.15 High Precision Radiotherapy E. Gkika (DE)
10.15-10.40 The use of R adiomics in Radiation Oncology C. Christopoulos (FR)
10.40-11.05 Radiotherapy and immunotherapy interactions:
perspectives in breast cancer treatment P. Tsoutsou (CH)

Chairs: V. Golfinopoulos (BE), Z. Saridak i (GR)
11.30-12.00 The transformation of the therapeutic landscape of HR+ HER2- breast cancer E. Thanopoulou (UK)
12.00-12.30 The potential of Liquid Biopsy in the management of cancer patients E. Lianidou (GR)

Chairs: D. Papadatos-Pastos (UK), P. Christopoulos (DE)
12.30-12.55 PD-L1 and other biomarkers for immunotherapy combinations in RCC P. Tsantoulis (CH)
12.55-13.20 Insights from the B cell response in patients with cancer for antibody therapy design S. Karagianni (UK)
13.20-13.45 CAR T cells: speeding on a race to beat cancer M. Themeli (NL)

Chairs: G. Patrinos (GR), I. Athanasiadis (GR)
15.00-15.30 Publishing: a cornerstone in the aim of cancer er adication A.- I. Zaromytidou (US)
15.30-16.00 The personalized medicine initiative and T-cell therapy in solid tumors. The MD Anderson Cancer Center experience A. Tsimperidou (US)

Chairs: A. Kotsakis (GR), K. Kosmatopoulos (FR)
16.00-16.25 Role of immunotherapy in SCCL K. Leventakos (US)
16.25-16.50 Metastatic Melanoma - latest evidence from early clinical trials P. Koliou (UK)
16.50-17.15 Development of immunotherapy with checkpoint inhibitors in breast cancer V. Karantza (US)
17.15-17.40 Treatment and prevention insights from the genomics of colorectal cancer M. Giannakis (US)

Chairs: K. Linos (US), N. Kar achaliou (DE)
18.00-18.25 The use of biomarkers in treating patients with metastatic breast cancer V. Kaklamani (US)
18.25-18.50 Functional Genomics could Guide Treatment of Advanced Cancer Patients G. Vasmatzis (US)
18.50-19.15 Functional assays in precision oncology: the Ex vivo approach P. Anastasiadis (US)

Z. Saridaki President of the Hellenic Society of Medical Oncology
V. Kouloulias President of the Hellenic Society of R adiation Oncology
V. Zolota Vice President of the Hellenic Society of P athology

Chairs: V. Georgoulias (GR), I. Boukovinas (GR)
19.30-20.00 ΕSMO: Promoting education, disseminating science and supporting professional development G. Pentheroudakis (CH)

Chairs: C. Sotiriou (ΒΕ), F.I. Dimitrakopoulos (GR)
09.30-09.55 The tumoral comprehensive molecular profiling V. Kotoula (GR)
09.55-10.20 Microchip technology for Cancer Diagnostics Μ. Kalofonou (UK)

Chairs: I. Mountzios (GR), A. Boutis (GR)
10.40-11.05 EGFR, ALK and other treatable mutations in NSCLC: current therapeutic algorithm P. Christopoulos (DE)
11.05-11.30 GU- prostate C. Alifragis (UK)
11.30-11.55 Targeted therapies for ER(+)/Her2(-) Breast cancer E. Papadimitraki (UK)
11.55-12.20 ΜPS1 inhibitors in TNBC S. Linardopoulos (UK)
12.20-12.45 Targeting HRD in Gynecological Cancer I. Athanasiadis (GR)
12.45-13.10 Melanoma - Targeted therapies in 2022: How and which? Y. Metaxas (CH)

Chairs: P. Kosmidis (GR), V. P elekanou (US)
14.30-14.55 Merging clinical, morphologic, protein and genomic data in mesenchymal and melanocytic neoplasia K. Linos (US)
14.55-15.20 New Drug Development Paradigms in Neurooncology: Bridging Basic Research with Clinical Trials E. Galani (US)
15.20-15.45 Perspective of Precision Medicine in Breast Cancer E. Andreopoulou (US)
15.45-16.10 Molecular determinants of response to KRAS G12C inhibitors in NSCLC F. Skoulidis (US)

Chairs: G. Vasmatzis (US), V. Karantza (US)
16.10-16.35 Harnessing Tumor Evolution and Immune Responses to Treat Lung Cancer V. Anagnostou (US)
16.35-17.00 Digital pathology and future perspectives in oncology V. Pelekanou (US)
17.00-17.25 The (r)evolution in the management of urothelial cancer: an evolving par adigm P. Grivas (US)

Chairs: N. Tsoukalas (GR), M. Rovithi (GR)
18.00-18.25 Clinical research in cancer palliative care: challenges and opportunities A. Konstantis (UK)
18.25-18.50 Ethical dilemmas at the end of life in cancer patients I. Boukovinas (GR)

Chairs: E. Lianidou (GR), F. Koinis (GR)
18.50-19.20 Pharma as a pillar in cancer research G. Carystinos (GR)
19.20-19.45 Maximizing Immunotherapy, Milestones and Future Outlook M. Karasarides (US)
19.45-20.10 A New paradigm for the Care of Prostate Cancer Patients C. Logothetis (US)

Αναγκαιότητα και Προοπτικές (Εκπαίδευση, Δημιουργία Δικτύων, Έρευνα)

Alifragris C.
MRCP, PhD, Consultant Medical Oncologist & Honorary Associate Professor University College London Hospital & St. Bartholomew’ s Hospital, UK
Anagnostou A.
MD, PhD, Assistant Professor, Medical Oncology Director, Thoracic Oncology Biorepository Upper Aerodigestive Oncology Program, Co-leader, Molecular Tumor Board, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, USA
Anastasiadis P.
PhD, Professor of Cancer Biology, Deputy Director: May o Clinic Cancer Center, Rochester, USA
Andreopoulou E.
MD, Professor of Clinical Medicine, Director of the Breast Canc er Center Clinical Research Program, Weill Cornell Medicine Breast Center , New York, USA
Athanasiadis I.
Medical Oncologist, Director of Oncologic Clinic MITERA Hospital, Assistant Professor of Oncology, Northwestern University, USA
Boukovinas I.
MD, PhD, PharmaD, Medical Oncologist, Head of Oncology Unit, Bioclinic Thessaloniki, Greece
Boutis A.
Medical Oncologist, Theagenio Cancer Hospital, Thessalonki, Greece
Carystinos G.
General Manager, Ipsen Greece, Cyprus and Israel
Christopoulos C.
Radiation Oncologist, Head of R adiation Oncology Department, Groupe Hospitalier de Territoire Grand Paris Nord-Est, Paris, France
Dimitrakopoulos F.I.
MD, PhD, Medical Oncologist, Division of Oncology & Molecular O ncology Laboratory, Department of Medicine, Univ ersity of Patras, Greece
Dimopoulos A.
MD, PhD, Director of Radiation Oncology, Department Metropolitan Hospital, Medical University of Vienna, Estro Faculty Member
Galani E.
MD, Professor of Oncology and Sandr a J. Schulze Professor of Nov el Therapeutics, Executive Dean of Development, Mayo Clinic, Rochester, Minnesota, USA - Chair, Neuro-Oncology Committee, Alliance for Clinical Trials in Oncology
Georgoulias Vasileios
Emeritus Professor of Medical Oncology, School of Medicine, Uni versity of Crete, Heraklion, Crete
Giannakis M.
MD, PhD, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute. Assistant Professor of Medicine, Harvar d Medical School, Boston, USA
Gkika E.
Assoc. Professor, Vice Chair of the department of Radiation Oncology, Universitätsklinikum Freiburg, Freiburg, Germany
Golfinopoulos V.
MD, PhD, Medical Oncologist, Director , European Organisation for Research and Treatment of Cancer (EORTC), EORTC Headquarters
Grivas P.
MD, PhD, Associate Professor, Department of Medicine, Division of Medical Oncology, Clinical Director, Genitourinary Cancers Program, University of Washington, Associate Professor, Clinical Research Division, F red Hutchinson Cancer Research Center , USA
Kaklamani V.
MD DSc, Professor of Medicine, Leader , Breast Oncology Program, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, USA
Kalofonou M.
PhD, Research Fellow Cancer T echnology Lead, Centre for Bio-Inspired Technology, Dept. of Electrical & Electronic Engineering, Institute of Biom edical Engineering, Imperial College London, London, UK
Karachaliou N.
MD, PhD, Medical Director, Global Clinical Development, Merck KGaA, Darmstadt, Germany
Karagiannis S.
Professor of Translational Cancer Immunology and Immunotherapy, St. John’s Institute of Dermatology, School of Basic & Medical Biosciences , King’s College London, Guy’s Hospital, London, UK
Karasarides M.
PhD, Vice President, Worldwide Medical Oncology, Early Assets and Biomarkers, BMS, USA
Klinakis A.
PhD, Director of Research - Professor lev el, Biomedical Research Foundation of the Academy of Athens, Greece
Koinis F.
Assistant Professor of Medical Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Greece
Koliou P.
BS, MSc, MD, PhD, Consultant Medical Oncologist, Breast Lead an d Melanoma, Royal Surrey NHS Foundation T rust, Guildford, UK
Konstantis A.
Consultant Medical Oncologist, Princess Alexandra Hospital and UCL NHS Trust, UK
Kosmatopoulos K.
Chief Executive Officer, Vaxon Biotech, Paris, France
Kosmidis P.
Head, Medical Oncologist, 2 nd Medical Oncology Department, Hy geia Hospital
Kotoula V.
MD, PhD, Associate Professor, Dept of Pathology, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, Greece
Kotsakis Athanasios
MD, PhD, Associate Professor of Medical Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Director of the Dpt of Medical Oncology University General Hospital of Larissa
Kouloulias V.
Professor of Radiation Oncology, School of Medicine, University of Athens, Scientific Director of Radiotherapy Unit, ATTIKON University Hospital, Athens, Greece
Leventakos K.
MD, PhD, Assistant Professor, Chest oncology and clinical studies phase 1, Mayo Clinic, Rochester, U.S.A.
Lianidou E.
PhD, Professor of Analytical Chemistry - Clinical Chemistry, Analysis of Circulating Tumor Cells Lab, Department of Chemistry, University of Athens, Greece
Linardopoulos S.
Associate Director, Translational Science, Oncology AstraZeneca - Professor of Cancer Therapeutics, The Insitute of Cancer Research, London, UK
Linos K.
MD, FCAP, FASDP, Associate Professor of Pathology, Geisel School of Medicine at Dartmouth, USA, Bone & Soft Tissue pathology and Dermatopathology Division, Director of Bone & Soft Tissue Pathology Division, Dartmouth Hitchcock Medical Center , USA
Liontos M.
PhD, Medical Oncologist, Consultant, Department of Clinical Therapeutics, Alexandra Hospital, Athens, Greece
Logothetis C.J.
MD, Professor, Department of Genitourinary Medical Oncology, UT MD Anderson Cancer Center, Houston, USA
Lygerou Z.
PhD, Professor, Head, Department of Gener al Biology, Director of Studies, MSc Life Sciences Informatics, School of Medicine, Univ ersity of Patras, Patras, Greece
Makatsoris T.
Medical Oncologist , Associate Professor, School of Medicine, University of Patras, Division of Medical Oncology, Univ ersity Hospital of Patras, Patra, Greece
Metaxas Y.
MD, Senior Consultant Medical Oncology, Cantonal Hospital Muen sterlingen, Switzerland
Mountzios I.
MD, MSc, PhD, Medical Oncologist, Director, 4th Oncology Department and Clinical Trials Unit, Henry Dunant Hospital Center, ONCOLIFE Institute founder, Athens, Greece
Papadatos-Pastos D.
MRCP (UK) PhD, Consultant in Medical Oncology, Lung Cancer and Acute Oncology, University College London Hospitals and The Princess Alexandra Hospital, London, UK
Papadimitraki E.
Consultant Medical Oncologist, Breast Unit and Early Phase Trials, University College London Hospital, UK
Patrinos G.
Professor of Pharmacogenomics and Pharmaceutical Biotechnology, Department of Pharmacy, University of Patras, Patras, Greece - Full Member and Greece ’s National representative, European Medicines Agency, CHMP-Pharmacogenomics Working Party, Amsterdam, the Netherlands
Pelekanou V.
MD, PhD, Digital Pathology Leader, Senior Director, Oncology Precision Medicine, Bay er
Pentheroudakis G.
MD PhD, Chief Medical Officer , ESMO, Lugano, Switzerland, Professor of Oncology, Medical School, Univ ersity of Ioannina
Rovithi M.
Medical Oncologist, Agios Nikolaos General Hospital, Crete, Greece
Saridaki Z.
MD, PhD, Medical Oncologist, Scientific Director of the Oncology Department Asklepios DIAGNOSIS, Asklepeion Crete Clinic, Heraklion, Crete, Greece
Skoulidis F.
MD, PhD, Assistant Professor, Department of Thoracic and Head and Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, U.S.A.
Sotiriou C.
MD, PhD, Head of the Breast Cancer T ranslational Research Laboratory, Université Libre de Bruxelles, Full Professor, Medical Oncology Department, Institut Jules Bor det, Brussels, Belgium
Thanopoulou E.
MD, MHA, PhD, Lead Clinical Director | GDC-0077, Product Development - Oncology, Roche Products Limited, UK
Themeli M.
MD PhD, Assistant Professor, Department of Hematology, Location Vumc, Cancer Center Amsterdam, Amsterdam, the Netherlands
Tsantoulis P.
MD, PhD, Medical Oncologist, Department of Oncology, Univ ersity Hospital of Geneva, Center for Translational Oncohematology, University of Geneva (HUG), Swiss Cancer Center Leman, Geneva, Switzerland
Tsimperidou A.
MD, PhD, Department of Inv estigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, USA
Tsoukalas N.
MD, MSc, PhD, Medical Oncologist, MSc Bioinf ormatics, Deputy Director, Oncology Department, 401 General Military Hospital and Consultant, Henry Dunant Hospital Center, Athens, Greece
Tsoutsou P.
MD PhD, Radiation Oncologist, Head of the R adiation Oncology Department, Geneva University Hospital, Geneva, Switzerland
Vasmatzis G.
Co-director of the Biomarker Discov ery Laboratory, Mayo Clinic Center for Individualized Medicine, Full Consultant in the Department of M olecular Medicine, Member of the Mayo Clinic Cancer Center, Rochester, USA
Zaromytidou A.I.
PhD, Chief Editor, Nature Cancer, Nature Portfolio, New York, NY

Αφού έχετε κάνει σύνδεση με τους κωδικούς σας (σε περίπτωση που δεν έχετε κωδικούς ακολουθήστε τη διαδικασία δημιουργίας λογαριασμού), πατήστε το κουμπί "Εγγραφείτε στην εκδήλωση".

Η καταγραφή του χρόνου παρακολούθησης αναγράφεται στη δεξιά πλευρά της σελίδας της εκδήλωσης που παρακολουθείτε. Η μέτρηση του χρόνου παρακολούθησης ξεκινάει εφόσον έχετε κάνει Subscription και εφόσον η εκδήλωση έχει ξεκινήσει. Η προβολή αυτού του πεδίου, πληροφορεί τον χρήστη για τον χρόνο (minutes) που έχει παρακολουθήσει.

Η εμφάνιση του pop-up window εξυπηρετεί στη διαφάνεια και στην αξιοπιστία των δεδομένων, που τελικά συλλέγονται μετά το πέρας της εκδήλωσης. Η διάρκεια εμφάνισης ενός pop-up window κατά την παρακολούθηση μίας live εκδήλωσης, είναι δύο λεπτά ενώ η επανάληψη εμφάνισης είναι περίπου ανά εξήντα λεπτά. Σε αυτό το διάστημα ο συμμετέχοντας της εκδήλωσης οφείλει να "απαντήσει", επιλέγοντας μία από τις δύο συνθήκες που εμφανίζονται στο pop-up window. Σε διαφορετική περίπτωση, το σύστημα θα διακόψει την καταγραφή του χρόνου παρακολούθησης.

Αφού έχετε κάνει σύνδεση και εγγραφή στην εκδήλωση, μπορείτε να υποβάλετε τις ερωτήσεις σας προς τους ομιλητές στο πεδίο που εμφανίζεται ακριβώς δίπλα στο παράθυρο αναμετάδοσης

Για να λάβετε το πιστοποιητικό σας, απαραίτητη προϋπόθεση είναι να έχετε επιλέξει το πεδίο "Εγγραφείτε στην εκδήλωση" καθώς και να έχετε παρακολουθήσει το 60% των συνολικών ωρών του επιστημονικού προγράμματος (αφορά σε ιατρικές επιστημονικές εκδηλώσεις). Στην σελίδα της εκδήλωσης και συμπληρώνοντας τη φόρμα αξιολόγησης, μπορείτε να λάβετε το πιστοποιητικό σας μέσω του πεδίου "ΚΑΤΕΒΑΣΤΕ ΤΟ ΠΙΣΤΟΠΟΙΗΤΙΚΟ ΣΑΣ". Τα πιστοποιητικά δίνονται με τη λήξη της επιστημονικής εκδήλωσης.

Ώρες λειτουργίας Τεχνικής Υποστήριξης:
- καθημερινά 09:00-17:00
- τις ημέρες του event 09:00-21:00
Μπορείτε να επικοινωνήσετε μαζί μας
στο τηλέφωνο +30 210 72 40 039
ή μέσω email support@livetime.gr

************************************

Technical Support is available:
- everyday 09:00-17:00
- at the day of the event 09:00-21:00
For Technical Support please contact us:
Phone: +30 210 72 40 039
Email: support@livetime.gr

Event Details